Business
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers
About this update from Voyager Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced seven data presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, taking place May 16-20, 2023, in Los Angeles. Accepted abstracts and the full preliminary program are available on the ASGCT website. Details for the presentations are as follows. TRACER™ AAV Capsid Discovery Platform Oral Presentation: Directed evolution of an AAV9 library identifies a capsid variant with enhanced brain tropism and liver de-targeting in non-human primates and mice following systemic administration. Tyler Moyer, Ph.D., Senior Scientist I, Novel Capsid Discovery. Thursday, May 18, 2023, 2:15 p.m. PT - 2:30 p.m. PT.Scientific Symposia: Discovery and characterization of novel cross-species BBB-penetrant capsids. Brett Hoffman, Ph.D., Senior Scientist II, Novel Capsid Discovery. Wednesday, May 17, 2023, 8:00 a.m. PT – 8:25 a.m. PT.Poster Presentation: Stepwise evolution of the AAV5-derived capsid VCAP-100 identifies novel variants with improved CNS transduction and liver de-targeting following systemic injection (#464). Damien Maura, Ph.D., Senior Scientist I, Novel Capsid Discovery. Wednesday, May 17, 2023, 12:00 p.m. PT - 2:00 p.m. PT.Poster Presentation: An evolved AAV variant with enhanced brain and spinal cord tropism and translation across primate species (#1393). Jing Lin, Ph.D., Scientist II, Novel Capsid Discovery. Friday, May 19, 2023, 12:00 p.m. PT - 2:00 p.m. PT. GBA-1 Gene Therapy Program Poster Presentation: Development of AAV-GBA1 gene replacement therapy via single-IV-delivery with a blood brain barrier penetrant AAV capsid. (#695). Charlotte Chung, Ph.D., Associate Director, Research. Wednesday, May 17, 2023, 12:00 p.m. PT - 2:00 p.m. PT. Technical Operations Poster Presentation: Effects of transgene size on self-complementary rAAV vectors (#1626). Amanda Ibe-Enwo, Ph.D, Senior Associate Scientist I, Technical Operations. Friday, May 19, 2023, 12:00 p.m. PT - 2:00 p.m. PT.Poster Presentation: rAAV produced by Sf9-baculovirus system shows different product quality profile throughout the production cycle (#394). Zeynep Guillemin. Senior Scientist I, Technical Operations. Wednesday, May 17, 2...